NCT05020704View on ClinicalTrials.gov

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions
Myocardial Infarction
Interventions
DRUG

Empagliflozin 10 MG

SGLT2inhibitor

DRUG

Placebo

Matched placebo

Trial Locations (3)

G4 0SF

Glasgow Royal Infirmary, Glasgow

G81 4HX

Golden Jubilee National Hospital, Glasgow

Unknown

NHS Greater Glasgow and Clyde, Glasgow

All Listed Sponsors
collaborator

University of Glasgow

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER